The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors.

Published on May 25, 2020in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2020.38.15_SUPPL.3568
Lisa Bodei25
Estimated H-index: 25
(MSK: Memorial Sloan Kettering Cancer Center),
Mark Kidd66
Estimated H-index: 66
+ 5 AuthorsIrvin M. Modlin81
Estimated H-index: 81
(Yale University)
3568Background: Peptide receptor radionuclide therapy (PRRT) is an effective therapy for metastatic/inoperable neuroendocrine tumors (NETs). Tools to predict and monitor the efficacy of therapy are...
📖 Papers frequently viewed together
8 Citations
38 Citations
Cited By1
#1Satya Das (VUMC: Vanderbilt University Medical Center)H-Index: 9
#2Liping Du (VUMC: Vanderbilt University Medical Center)H-Index: 22
Last. Jordan Berlin (VUMC: Vanderbilt University Medical Center)H-Index: 67
view all 14 authors...
We developed a clinical score (CS) at Vanderbilt Ingram Cancer Center (VICC) that we hoped would predict outcomes for patients with progressive well-differentiated neuroendocrine tumors (NETs) receiving therapy with Lutetium-177 (177Lu)-DOTATATE. Patients under consideration for 177Lu-DOTATATE between 3/1/2016-3/17/2020 at VICC were assigned a CS prospectively. The CS included 5 categories: available treatments for tumor type outside of 177Lu-DOTATATE, prior systemic treatments, patient symptoms...